Related Experiment Videos
Progressive hypokalaemia in elderly patients taking three thiazide potassium-sparing diuretic combinations for
Insights
Spironolactone may be the best thiazide potassium-sparing diuretic combination for elderly heart failure patients, showing fewer discontinuations due to low potassium levels. Triamterene showed a trend toward greater potassium reduction.
Area of Science:
- Cardiology
- Geriatrics
- Pharmacology
Background:
- Elderly patients with heart failure often require diuretic therapy.
- Potassium balance is a critical concern with diuretic use, especially in older adults.
Purpose of the Study:
- To compare the efficacy and safety of three thiazide potassium-sparing diuretic combinations in elderly heart failure patients.
- To assess the incidence of hypokalemia and treatment discontinuation across different diuretic combinations.
Main Methods:
- A 3-year prospective study involving elderly heart failure patients.
- Randomized allocation to three different thiazide potassium-sparing diuretic combinations.
- Regular monitoring of plasma potassium levels and recording of reasons for treatment withdrawal.
Main Results:
- The triamterene-containing preparation had the highest discontinuation rate due to hypokalemia (plasma potassium < 3.0 mmol/l).
- Amiloride also showed a notable rate of discontinuation for hypokalemia.
- Spironolactone had the lowest discontinuation rate for hypokalemia.
- The median fall in plasma potassium over 3 years was similar across groups, though a trend towards greater reduction with triamterene was observed.
Conclusions:
- Spironolactone-containing diuretic combinations appear to be the most suitable option for elderly heart failure patients regarding potassium management.
- High withdrawal rates due to hypokalemia were observed, particularly with triamterene and amiloride.
- Further investigation may be warranted to confirm the trend of greater potassium reduction with triamterene.
Abstract:
Three different thiazide potassium-sparing diuretic combinations were given to elderly patients for heart failure. Eighty patients received their allocated combinations for 3 years and had 6-monthly measurements of plasma potassium. A further 84 were recruited for study but 29 died within 6 months and 55 had to be withdrawn from the trial. The triamterene-containing preparation was discontinued most frequently (6/44) because of hypokalaemia (plasma potassium less than 3.0 mmol/l); amiloride (5/44) and spironolactone (1/47). The median fall in plasma potassium over 3 years in those patients not withdrawn because of hypokalaemia was similar in each case (P greater than 0.05) and possibly failed to reach significance because of the withdrawal rate (9%). The trend was for a greater fall in those patients taking triamterene. The spironolactone-containing preparation may be the least unsatisfactory of the three.